

London Cancer Haematology Tumour Pathway Board Annual Report 2017-18

Introduction

London Cancer incorporates the geographical areas of North Central and East London and West Essex with a population of 3.7 million. Since 2016, London Cancer has become one of the six principal programmes of the UCLH Cancer Collaborative.

The Haematology Tumour Pathway Board, led by Professor Ron Chakraverty, is responsible for driving improvement across the whole haematological care pathway. The Board's membership includes multi-disciplinary representation from cancer professionals across the region and active participation from primary care and from patients.

The role of each pathway board is to understand any variation in practice and set standards that take advantage of planning whole pathways of cancer care for a large population. This drive to improve cancer care for patients covers an integrated care pathway that extends from presentation and diagnosis through to palliative care and living with and beyond cancer.

In the past year the board has again seized the unique opportunities made possible our vanguard status to collaborate with our Greater Manchester and RM Partners counterparts, south east London colleagues, data experts, and specialists from other tumour groups to improve our services. We anticipate an exciting 2018/19 as the results of these collaborations begin to bear fruit. To pick out a couple of highlights; our data dashboard will allow services to monitor performance and quickly remedy any issues and the efforts of the lymphoma breaches working group should spark an improvement in our cancer waiting times performance.

Achievements this year

2017/18 has seen the board embark on collaborations with our Vanguard and South East London colleagues in developing an innovative online GP myeloma education module and in creation of pan London clinical guidelines.

We have focussed on fostering closer working relationships initially between our hospitals by working towards standardised radiology reporting and secondly with other tumour types via removal of obstacles to speedy suspected lymphoma referrals.

Our key achievements have been:

- Holding the first pan-London haematology clinical guidelines and education day. It is hoped that this will become an annual event.
- Development of 11 clinical guidelines with colleagues from across London. Final editing is now being undertaken before an expected summer 2018 publication.
- NHS London have authorised progression through gateway 5 of the service reconfiguration process. This required demonstration that the expected benefits of the reconfiguration have been realised.



Professor Ronjon Chakraverty, Pathway Director & Professor of Haematology and Cellular Immunotherapy at Royal Free

UCLH Cancer Collaborative brings together hospital trusts, GPs, health service commissioners, local authorities and patients across north and east London and west Essex.

- UCLH lymphoma consultants collaborated with the centre for cancer outcomes team to create a dashboard that pulls in all available performance data into one place, allowing teams to have the most up to date information about their service at their fingertips. Next year we will explore modifying the system for other Trusts.
- Establishment of a lymphoma 62 day breaches working group. The group has generated a set of actions with a view to achieving the cancer waiting times standard.
- Auditing radiology reports with a view to standardising reports across the patch. Results of the audit are to be presented at our May board.
- Wai-Keong Wong, board member and consultant haematologist has developed trialslink.com, a website that enables clinicians and patients to easily view which trials may be appropriate for their patients/themselves. The board will explore how they can support the spread of trialslink.com.
- Publication of 6 patient information films in 9 languages. The 'Having a Bone Marrow Test' has been viewed over 100,000 times since publication.

Patient representation

Our patient representatives have been crucial in developing our projects, ensuring effect on patients is the focus of all that we do.

Future plans

In 2018/19 we will facilitate earlier diagnosis and build on the foundations laid in the previous year to improve patient experience. Our work plan is outlined below.

No	Objective	Owner	By
1	Complete development of a myeloma 'gateway C' (GP education) module with Greater Manchester Cancer and oversee its roll out in our patch.	SE/RC/NR/HaH	March 2019
2	Publish pan-London guidelines by summer 2018	SE/RC/RM Partners/South East London	March 2019
3	Help Trusts move towards standardised radiology reporting.	All board members	March 2019
4	Lymphoma 62 day breaches working group to improve engagement with high referral tumour sites	SE/WT	March 2019
5	Complete the development of patient experience specification and audit against it.	SE/CNS & Patient representatives	September 2018

Acknowledgements

We would like to thank all the members of the Haematology Tumour Pathway Board for contributing their time to Tumour Pathway Board meetings and projects outside the meeting.

Special thanks to our patient representative Declan Sheehan, Peter Bion and Gilly Angel who have provided their expertise as users of services to understand where we can have biggest impact on improving our hospitals for the benefit of patients.